Allergan Re-submits Application
Following discussions with the Scottish Medicines Consortium (SMC), Allergan will re-submit an application for OZURDEX for adult patients with macular oedema due to retinal vein occlusion (RVO) in early 2012. A company spokesman said that while Allergan was surprised and disappointed to learn of the SMC’s decision not to recommend OZURDEX for use in the National Health Service in Scotland, the company is committed to bringing the medication to Scottish patients with either form of RVO; central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
“This is particularly important for Scottish patients with BRVO who do not currently have a reimbursed pharmacological treatment option,†he said.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.